Concurrently, Viking is conducting the Phase 3 VANQUISH-2 study of subcutaneous VK2735 in patients with type 2 diabetes who have obesity or are overweight. That trial is currently enrolling patients, ...

Beyond the kitchen doors, Greenwood itself is part of the magic. The school is situated right downtown, near the Alluvian ...

For meal preparation, dual-oven gas ranges are an exceptional choice, removing the need for two distinct ovens. These ranges allow you to prepare a greater quantity of food simultaneously, providing a ...

Earnings call Viking Therapeutics reported a Q3 2025 net loss of $90.8M ($0.81/share), up from $24.9M YoY, driven by a 294% surge in R&D expenses. The company highlighted strong phase 2 results for ...

Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Proceeding on Schedule VK2735 Phase 1 Maintenance Dosing Study Underway Additional Phase 2a VENTURE Study Data to be Presented at ObesityWeek ...

The maintenance dosing study is a Phase 1, randomized, double-blind, placebo-controlled trial in approximately 180 adults with obesity (BMI ≥30 kg/m 2) and otherwise healthy. All participants will ...

Hundreds of people turned out to watch the Faversham Carnival in Kent this evening (October 11). The annual illuminated parade featured a wide range of floats ranging from a double decker bus to ...

Viking Therapeutics' shares tanked recently after its oral drug, VK2735, spooked investors with a high discontinuation rate. However, it achieved weight loss results similar to Eli Lilly's drug.